Profile data is unavailable for this security.
About the company
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
- Revenue in USD (TTM)207.78m
- Net income in USD451.00k
- Incorporated1989
- Employees314.00
- LocationVericel Corp64 Sidney StCAMBRIDGE 02139-4170United StatesUSA
- Phone+1 (734) 930-5555
- Fax+1 (734) 665-0485
- Websitehttps://vcel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.12bn | 1.76k | 14.94 | 3.15 | 10.55 | 3.13 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.13bn | 1.54k | -- | -- | -- | 2.13 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.15bn | 500.00 | -- | 5.35 | -- | 46.42 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.20bn | 624.00 | -- | 14.28 | 460.33 | 7.75 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.63 | -- | 12.61 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.23bn | 64.00 | -- | 3.40 | -- | 306.11 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.28bn | 226.00 | -- | 37.00 | -- | 24.79 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Fortrea Holdings Inc | 3.01bn | -102.40m | 2.30bn | 18.00k | -- | 1.43 | -- | 0.7641 | -1.15 | -1.38 | 33.80 | 17.92 | 0.7027 | -- | 3.10 | -- | -2.39 | -- | -2.89 | -- | 16.64 | -- | -3.41 | -- | -- | 0.0877 | 0.5019 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Vericel Corp | 207.78m | 451.00k | 2.33bn | 314.00 | 5,019.88 | 9.95 | 431.93 | 11.23 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.39bn | 160.00 | -- | 2.85 | -- | 394.25 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.40bn | 497.00 | -- | 6.64 | -- | 9.03 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.40bn | 526.00 | -- | 2.31 | -- | 45.63 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.40bn | 1.45k | -- | 6.68 | -- | 4.57 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Twist Bioscience Corp | 277.49m | -192.14m | 2.41bn | 919.00 | -- | 4.29 | -- | 8.68 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.41bn | 445.00 | -- | 3.95 | -- | 33.81 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
Data as of May 23 2024. Currency figures normalised to Vericel Corp's reporting currency: US Dollar USD
58.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.28m | 15.05% |
| Brown Capital Management LLCas of 31 Mar 2024 | 4.95m | 10.23% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.29m | 6.79% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.21m | 6.65% |
| Conestoga Capital Advisors LLCas of 31 Mar 2024 | 2.33m | 4.82% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.08m | 4.31% |
| RTW Investments LPas of 31 Mar 2024 | 1.61m | 3.32% |
| GW&K Investment Management LLCas of 31 Mar 2024 | 1.23m | 2.53% |
| Loomis, Sayles & Co. LPas of 31 Mar 2024 | 1.11m | 2.29% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 1.08m | 2.24% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
